XML 51 R33.htm IDEA: XBRL DOCUMENT
v3.26.1

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) | 3 Months Ended
--- | ---
Apr. 03, 2026
Fair Value Disclosures [Abstract] |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
| Fair Value |  | Quoted Prices in Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
April 3, 2026 |  |  |  |  |  |  |
Assets: Foreign currency hedging contracts | $ | 3,480 |  |  | $ | — |  |  | $ | 3,480 |  |  | $ | — |
Liabilities: Foreign currency hedging contracts | 1,919 |  |  | — |  |  | 1,919 |  |  | — |
Liabilities: Contingent consideration | 8,179 |  |  | — |  |  | — |  |  | 8,179 |
December 31, 2025 |  |  |  |  |  |  |
Liabilities: Foreign currency hedging contracts | $ | 5,221 |  |  | $ | — |  |  | $ | 5,221 |  |  | $ | — |
Liabilities: Contingent consideration | 8,179 |  |  | — |  |  | — |  |  | 8,179 |
Information regarding outstanding foreign currency forward contracts as of April 3, 2026 is as follows (dollars in thousands):
Notional Amount |  | Maturity Date |  | $/Foreign Currency |  | Fair Value |  | Balance Sheet Location
$ | 38,320 |  |  | Apr 2027 |  | 0.0507 |  | MXN Peso |  | $ | 3,395 |  |  | Prepaid expenses and other current assets
1,543 |  |  | Oct 2026 |  | 0.2421 |  | MYR Ringgit |  | 42 |  |  | Prepaid expenses and other current assets
1,967 |  |  | Oct 2026 |  | 0.0242 |  | UYU Peso |  | 43 |  |  | Prepaid expenses and other current assets
50,362 |  |  | Dec 2026 |  | 1.1826 |  | Euro |  | (1,012) |  |  | Accrued expenses and other current liabilities
11,215 |  |  | Apr 2027 |  | 0.0564 |  | MXN Peso |  | (325) |  |  | Accrued expenses and other current liabilities
3,680 |  |  | Apr 2027 |  | 0.2588 |  | MYR Ringgit |  | (132) |  |  | Accrued expenses and other current liabilities
11,043 |  |  | Apr 2027 |  | 0.0256 |  | UYU Peso |  | (367) |  |  | Accrued expenses and other current liabilities
3,969 |  |  | Jul 2027 |  | 0.0550 |  | MXN Peso |  | (83) |  |  | Other long-term liabilities
Information regarding outstanding foreign currency forward contracts as of December 31, 2025 is as follows (dollars in thousands):
Notional Amount |  | Maturity Date |  | $/Foreign Currency |  | Fair Value |  | Balance Sheet Location
$ | 15,906 |  |  | Oct 2026 |  | 1.1610 |  | Euro |  | $ | 266 |  |  | Prepaid expenses and other current assets
7,649 |  |  | Oct 2026 |  | 0.0244 |  | UYU Peso |  | 383 |  |  | Prepaid expenses and other current assets
51,699 |  |  | Dec 2026 |  | 0.0501 |  | MXN Peso |  | 4,491 |  |  | Prepaid expenses and other current assets
2,959 |  |  | Oct 2026 |  | 0.2401 |  | MYR Ringgit |  | 82 |  |  | Prepaid expenses and other current assets
3,842 |  |  | Apr 2027 |  | 0.0519 |  | MXN Peso |  | 76 |  |  | Other long-term assets
8,923 |  |  | Jul 2026 |  | 1.1898 |  | Euro |  | (77) |  |  | Accrued expenses and other current liabilities
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) | The following tables present the effect of cash flow hedge derivative instruments on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income for the three and three months ended April 3, 2026 and March 28, 2025 (in thousands):
|  | Three Months Ended
|  | April 3, 2026 |  | March 28, 2025
|  | Total |  | Amount of Gain (Loss) on Cash Flow Hedge Activity |  | Total |  | Amount of Gain (Loss) on Cash Flow Hedge Activity
Sales |  | $ | 439,580 |  |  | $ | (116) |  |  | $ | 437,392 |  |  | $ | (583) |
Cost of sales |  | 329,985 |  |  | (2,819) |  |  | 317,074 |  |  | (693) |
Operating expenses |  | 77,726 |  |  | — |  |  | 70,766 |  |  | (17) |
(13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
|  | Unrealized Gain (Loss) Recognized in OCI |  | Realized Gain (Loss) Reclassified from AOCI
|  | Three Months Ended |  | Location in Statements of Operations and Comprehensive Income |  | Three Months Ended
|  | April 3, 2026 |  | March 28, 2025 |  |  | April 3, 2026 |  | March 28, 2025
Foreign exchange contracts |  | $ | (1,407) |  |  | $ | 1,808 |  |  | Sales |  | $ | (116) |  |  | $ | (583) |
Foreign exchange contracts |  | (5,096) |  |  | 2,419 |  |  | Cost of sales |  | (2,819) |  |  | (693) |
Foreign exchange contracts |  | (92) |  |  | 349 |  |  | Operating expenses |  | — |  |  | (17) |
Schedule of Estimated Fair Values for Contingent Consideration | The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for the three and three months ended April 3, 2026 and March 28, 2025 (in thousands):
| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Fair value measurement at beginning of period | $ | 8,179 |  |  | $ | 904 |  |  |  |  |
Amount recorded for current year acquisitions | — |  |  | 2,541 |  |  |  |  |
Fair value measurement at end of period | $ | 8,179 |  |  | $ | 3,445 |  |  |  |  |
Schedule of Equity Method and Other Investments | Equity and other investments comprise the following (in thousands):
|  |  |  |  | April 3, 2026 |  | December 31, 2025
Equity method investment |  |  |  |  | $ | 6,197 |  |  | $ | 7,709 |
Non-marketable equity securities |  |  |  |  | 180 |  |  | 180 |
Convertible debt instrument |  |  |  |  | 13,849 |  |  | — |
Total equity and other investments |  |  |  |  | $ | 20,226 |  |  | $ | 7,889 |
During the first quarter of 2026, the Company invested 12 million euro ($13.8 million) in a convertible debt instrument issued by a life sciences company that matures on December 31, 2035. The instrument has a stated interest of 4.55%, payable periodically during the term of the instrument. Depending on certain operational and financial targets, the Company may invest an additional 3 million euro under the same terms. The instrument is senior to all other indebtedness, and is secured by the assets of the investee. The Company considered guidance within ASC 815 and concluded the conversion option did not require bifurcation as an embedded derivative instrument. The components of (Gain) loss on equity investments for each period were as follows (in thousands):
| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Equity method investment (gain) loss | $ | 1,468 |  |  | $ | (181) |  |  |  |  |
Schedule of Business Combination, Contingent Consideration | The following table provides information on unpaid contingent consideration as of April 3, 2026 (in thousands):
|  |  |  |  |  | As of April 3, 2026
|  |  |  |  |  | Maximum Remaining Payout (undiscounted) |  |
Acquisition |  | Acquisition Date |  | RemainingMilestone Years |  | 2026 |  | 2027 |  | 2028 |  | 2029 |  | Total |  | Fair Value
Biocoat |  | 12/04/25 |  | 2026 |  | $ | 7,000 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 7,000 |  |  | $ | 7,000 |
VSi |  | 02/28/25 |  | 2026 - 2028 |  | — |  |  | 1,000 |  |  | 1,000 |  |  | 1,000 |  |  | 3,000 |  |  | 1,179 |
InNeuroCo |  | 10/01/23 |  | 2026 - 2027 |  | — |  |  | 2,700 |  |  | 2,700 |  |  | — |  |  | 5,400 |  |  | — |

X
- Definition Schedule Of Equity Method And Other Investments + References No definition available. + Details
Name: | itgr_ScheduleOfEquityMethodAndOtherInvestmentsTableTextBlock
Namespace Prefix: | itgr_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details
Name: | us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration